Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib monotherapy maintenance in platinum-sensitive relapsed ovarian cancer after response to platinum chemotherapy
CTR20180489Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of olaparib in ovarian cancer, primary peritoneal cancer (PPC), fallopian tube cancer (PFTC), sponsored by AstraZeneca. Started Jun 2018; status: completed.
02
Drugs
olaparib
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on CTR20180489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180489.